{
  "timeline": [
    {
      "date": "1897/5",
      "category": "会社設立",
      "region": "",
      "importance": 3,
      "event": "大阪製薬を設立",
      "detail": "大阪市道修町の有力薬業家21名により設立",
      "significance": "後の住友ファーマの源流となる創業",
      "source": "有価証券報告書",
      "amount": "創業者21名"
    },
    {
      "date": "1898/9",
      "category": "設備投資",
      "region": "",
      "importance": 1,
      "event": "大阪工場設置",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1898/11",
      "category": "企業買収",
      "region": "",
      "importance": 2,
      "event": "大日本製薬合資会社を買収し社名変更",
      "detail": "大日本製薬株式会社に改称",
      "significance": "大日本製薬としての出発点",
      "source": "有価証券報告書"
    },
    {
      "date": "1908/7",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "大阪薬品試験を吸収合併",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1947/10",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "五協産業を設立",
      "detail": "後のDSP五協フード&ケミカル",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1949/5",
      "category": "株式上場",
      "region": "",
      "importance": 2,
      "event": "大阪・東京両証券取引所に株式上場",
      "detail": "1961年10月に両取引所市場第一部に指定",
      "significance": "株式会社としての本格的な資本市場進出",
      "source": "有価証券報告書"
    },
    {
      "date": "1968/10",
      "category": "設備投資",
      "region": "",
      "importance": 1,
      "event": "鈴鹿工場設置",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1971/2",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "総合研究所設置",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1993/1",
      "category": "",
      "region": "米州",
      "importance": 2,
      "event": "米国現地法人Dainippon Pharmaceutical U.S.A.設立",
      "detail": "後のDainippon Sumitomo Pharma America",
      "significance": "北米進出の足がかり",
      "source": "有価証券報告書"
    },
    {
      "date": "2003/4",
      "category": "設備投資",
      "region": "",
      "importance": 1,
      "event": "大阪工場閉鎖・鈴鹿工場へ生産統合",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2005/10",
      "category": "組織再編",
      "region": "",
      "importance": 4,
      "event": "住友製薬と合併し大日本住友製薬に",
      "detail": "茨木工場・愛媛工場・大分工場・大阪研究所他および住友制葯（蘇州）を承継",
      "significance": "大日本製薬と住友製薬の経営統合により業界中堅メーカーが誕生",
      "source": "有価証券報告書"
    },
    {
      "date": "2005/6",
      "category": "社長交代",
      "region": "",
      "importance": 2,
      "event": "宮武健次郎が初代社長に就任",
      "detail": "合併後の大日本住友製薬の初代代表取締役社長",
      "significance": "合併会社の経営体制発足",
      "source": "有価証券報告書"
    },
    {
      "date": "2008/6",
      "category": "社長交代",
      "region": "",
      "importance": 2,
      "event": "多田正世が社長に就任",
      "detail": "",
      "significance": "大日本住友製薬の事業基盤確立期を率いた経営者",
      "source": "有価証券報告書"
    },
    {
      "date": "2009/7",
      "category": "",
      "region": "米州",
      "importance": 1,
      "event": "米国Dainippon Sumitomo Pharma America Holdings設立",
      "detail": "後のSumitomo Pharma America",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2009/10",
      "category": "企業買収",
      "region": "米州",
      "importance": 4,
      "event": "米国Sepracor Inc.を買収",
      "detail": "後のSunovion Pharmaceuticals。Dainippon Sumitomo Pharma America Holdingsを通じて買収",
      "significance": "北米展開の本格化と中枢神経領域強化の起点",
      "source": "有価証券報告書",
      "amount": "買収価格約26億ドル"
    },
    {
      "date": "2010/4",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "SepracorがDainippon Sumitomo Pharma Americaを吸収合併",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2010/7",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "アニマルサイエンス事業とフード&スペシャリティ事業を会社分割",
      "detail": "DSファーマアニマルヘルスとDSP五協フード&ケミカルへ承継",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2012/4",
      "category": "企業買収",
      "region": "米州",
      "importance": 3,
      "event": "米国Boston Biomedical, Inc.を買収",
      "detail": "がん領域強化を目的とした米国バイオ企業の取得",
      "significance": "がん領域への本格参入",
      "source": "有価証券報告書",
      "amount": "買収価格約2億ドル+マイルストン"
    },
    {
      "date": "2013/1",
      "category": "",
      "region": "東南アジア",
      "importance": 1,
      "event": "シンガポールにSunovion Pharmaceuticals Asia Pacific設立",
      "detail": "現Sumitomo Pharma Asia Pacific",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2013/7",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "東京支社を東京本社に改称・東西両本社制へ",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2017/1",
      "category": "企業買収",
      "region": "米州",
      "importance": 2,
      "event": "米国Tolero Pharmaceuticals, Inc.を買収",
      "detail": "オンコロジー領域の拡大",
      "significance": "がん領域の北米パイプライン拡充",
      "source": "有価証券報告書"
    },
    {
      "date": "2018/6",
      "category": "社長交代",
      "region": "",
      "importance": 2,
      "event": "野村博が社長に就任",
      "detail": "",
      "significance": "ラツーダ時代のピーク期から減損期までを率いた経営者",
      "source": "有価証券報告書"
    },
    {
      "date": "2019/4",
      "category": "設備投資",
      "region": "",
      "importance": 1,
      "event": "茨木工場・愛媛工場を廃止",
      "detail": "鈴鹿工場と大分工場の2拠点体制に再編",
      "significance": "生産拠点の効率化",
      "source": "有価証券報告書"
    },
    {
      "date": "2019/12",
      "category": "企業買収",
      "region": "米州",
      "importance": 4,
      "event": "Roivant Sciencesと戦略的提携・Sumitovant Biopharma子会社化",
      "detail": "Roivantの子会社群を一括取得しパイプライン獲得",
      "significance": "ラツーダLOE後の北米事業の柱とすべく実施した大型ディール",
      "source": "有価証券報告書",
      "amount": "出資総額約30億ドル"
    },
    {
      "date": "2020/7",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "Boston BiomedicalがTolero吸収合併・商号変更",
      "detail": "Sumitomo Dainippon Pharma Oncology（現Sumitomo Pharma America）に商号変更",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/4",
      "category": "",
      "region": "",
      "importance": 3,
      "event": "商号を住友ファーマに変更・プライム市場へ移行",
      "detail": "東証市場区分見直しにより市場第一部からプライム市場へ移行",
      "significance": "大日本住友製薬時代の終焉と新生住友ファーマの始動",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/6",
      "category": "",
      "region": "中国",
      "importance": 1,
      "event": "住友制葯投資（中国）を設立",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/10",
      "category": "",
      "region": "米州",
      "importance": 3,
      "event": "キンモビ減損544億円計上・営業赤字転落",
      "detail": "2016年シナプサス社買収（6.35億ドル）により獲得したキンモビが想定を大幅に下回り減損",
      "significance": "北米M&A拡大路線の躓きを示す象徴的事象。後の巨額減損の前兆",
      "source": "IR",
      "amount": "減損損失544億円・四半期営業損失289億円"
    },
    {
      "date": "2023/3",
      "category": "事業売却",
      "region": "",
      "importance": 2,
      "event": "住友ファーマフード&ケミカル全株式をメディパルHDに譲渡",
      "detail": "",
      "significance": "事業の選択と集中の一環",
      "source": "有価証券報告書"
    },
    {
      "date": "2023/5",
      "category": "事業売却",
      "region": "",
      "importance": 2,
      "event": "住友ファーマアニマルヘルス全株式を三井物産に譲渡",
      "detail": "",
      "significance": "中期経営計画2027に基づく事業ポートフォリオ再編",
      "source": "有価証券報告書"
    },
    {
      "date": "2023/5",
      "category": "経営計画",
      "region": "",
      "importance": 3,
      "event": "中期経営計画2027を発表",
      "detail": "基幹3製品集中とパイプライン絞り込み・北米人員大幅削減を打ち出す",
      "significance": "ラツーダLOE後の構造改革の方針確立",
      "source": "IR",
      "amount": "販管費670億円減・研究開発費500億円計画"
    },
    {
      "date": "2023/7",
      "category": "組織再編",
      "region": "米州",
      "importance": 4,
      "event": "米国グループ会社7社をSumitomo Pharma Americaに統合再編",
      "detail": "Sunovion・Sumitovant・Myovant等を1社に集約",
      "significance": "北米事業の歴史的統合により大日本住友製薬時代の拡大路線が一旦完結",
      "source": "有価証券報告書",
      "amount": "北米人員約500人削減・コストシナジー約2.6億ドル"
    },
    {
      "date": "2023/9",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "Myovant Sciences GmbHをSumitomo Pharma Switzerland GmbHに商号変更",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2024/3",
      "category": "",
      "region": "",
      "importance": 5,
      "event": "FY23通期で純損失3,150億円規模・巨額のれん減損",
      "detail": "基幹3製品の事業計画未達によるのれん・無形資産の大規模減損",
      "significance": "住友ファーマ史上最大の赤字決算で経営危機が顕在化",
      "source": "IR",
      "amount": "純損失約3,150億円"
    },
    {
      "date": "2024/5",
      "category": "社長交代",
      "region": "",
      "importance": 3,
      "event": "木村徹が代表取締役社長に就任",
      "detail": "野村博から経営バトンを受ける急遽の社長交代",
      "significance": "経営危機下での体制刷新・住友化学のガバナンス強化を背景とした新体制",
      "source": "IR"
    },
    {
      "date": "2024/11",
      "category": "構造改革",
      "region": "",
      "importance": 3,
      "event": "日本国内で早期退職募集・2,000名体制へ",
      "detail": "北米に続き国内でもリストラを実施",
      "significance": "住友ファーマ史上初の大規模国内人員削減",
      "source": "IR",
      "amount": "2,000名体制への削減"
    },
    {
      "date": "2025/2",
      "category": "事業売却",
      "region": "",
      "importance": 3,
      "event": "再生・細胞医薬事業を会社分割しRACTHERAに承継・株式66.6%を住友化学に譲渡",
      "detail": "",
      "significance": "事業ポートフォリオの選択と集中の一環",
      "source": "有価証券報告書",
      "amount": "譲渡益約120億円見込み"
    },
    {
      "date": "2025/3",
      "category": "",
      "region": "",
      "importance": 3,
      "event": "FY24通期で当期利益236億円のV字回復",
      "detail": "前年▲3,150億円から+3,386億円の劇的改善",
      "significance": "構造改革1年目で黒字化を達成し再建ストーリーが市場で評価された",
      "source": "IR",
      "amount": "コア営業利益432億円・営業利益288億円"
    },
    {
      "date": "2025/5",
      "category": "経営計画",
      "region": "",
      "importance": 3,
      "event": "新中期経営計画Reboot 2027を発表",
      "detail": "アジア事業合弁化・フロンティア事業譲渡で米日集中ビジネスモデルへ転換",
      "significance": "大日本住友製薬時代の拡大路線を完全清算し新たなビジネスモデルへ転換",
      "source": "IR",
      "amount": "アジア事業合弁譲渡対価計720億円"
    },
    {
      "date": "2025/8",
      "category": "合弁設立",
      "region": "中国",
      "importance": 3,
      "event": "中国・アジア事業を丸紅グローバルファーマとの合弁に移管",
      "detail": "25年度60%・28年度40%の2段階で合弁化",
      "significance": "米日集中戦略の具体化と財務体質改善",
      "source": "IR",
      "amount": "譲渡益490億円"
    },
    {
      "date": "2025/3",
      "category": "組織再編",
      "region": "米州",
      "importance": 1,
      "event": "米国子会社SMPA・スイス子会社SMPSを直接子会社化",
      "detail": "グループ資本再編の一環",
      "significance": "",
      "source": "IR"
    },
    {
      "date": "2025/6",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "監査等委員会設置会社へ移行",
      "detail": "定時株主総会で承認",
      "significance": "ガバナンス体制強化",
      "source": "IR"
    },
    {
      "date": "2025/9",
      "category": "",
      "region": "",
      "importance": 3,
      "event": "FY25通期予想を過去最高水準に上方修正",
      "detail": "オルゴビクス10億ドル到達見込み等で再建完全達成へ",
      "significance": "住友ファーマの再建成功を内外に示す節目",
      "source": "IR",
      "amount": "コア営業利益970億円・当期利益920億円予想"
    }
  ]
}